Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinicopathologic and protein markers distinguishing the "polymerase epsilon exonuclease" from the "copy number low" subtype of endometrial cancer.

Journal of gynecologic oncology - 1 May 2022

Kim Kidong, Hwangbo Suhyun, Kim Hyojin, Kim Yong Beom, No Jae Hong, Suh Dong Hoon, Park Taesung

Abstract excerpt

OBJECTIVE: The need to perform genetic sequencing to diagnose the polymerase epsilon exonuclease (POLE) subtype of endometrial cancer (EC) hinders the adoption of molecular classification. We investigated clinicopathologic and protein markers that distinguish the POLE from the copy number (CN)-low subtype in EC. METHODS: Ninety-one samples (15 POLE, 76 CN-low) were selected from The Cancer Genome Atlas EC...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Caspase 8
Share to Cyclin B1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Copy Number Variations

Share to DNA Polymerase II

Share to Endometrial Neoplasms

Share to Exonucleases

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 35128857
DOI: 10.3802/jgo.2022.33.e27
PMCID: PMC9024182

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinicopathologic and protein markers distinguishing the "polymerase epsilon exonuclease" from the "copy number low" subtype of endometrial cancer.PMID 35128857Read ↗

Clinicopathological and molecular characterization of high-grade endometrial carcinoma with POLE mutation: a single center study.Semantic proximity Read ↗

The clinicopathology and survival characteristics of patients with POLE proofreading mutations in endometrial carcinoma: A systematic review and meta-analysis.Semantic proximity Read ↗

Molecular Characterization and Clinical Implications of Endometrial Cancer.Semantic proximity Read ↗

The TCGA Molecular Classification of Endometrial Cancer and Its Possible Impact on Adjuvant Treatment DecisionsSemantic proximity Read ↗

High-grade endometrial carcinomas: Morphologic spectrum and molecular classification.Semantic proximity Read ↗

Targeted Molecular and Immunohistochemical Analyses of Endometrial Clear Cell Carcinoma Show that POLE Mutations and DNA Mismatch Repair Protein Deficiencies Are UncommonSemantic proximity Read ↗

Endometrial Cancer: Transitioning from Histology to Genomics.Semantic proximity Read ↗

Clinicopathological characteristics and prognostic value of POLE mutations in endometrial cancer: A systematic review and meta-analysis.Semantic proximity Read ↗

Clinical Application of Next-Generation Sequencing for Molecular Classification in the Management of Endometrial Cancer: An Observational Cohort StudySemantic proximity Read ↗

Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations.Semantic proximity Read ↗

Identification of molecular subtypes for endometrial carcinoma using a 46-gene next-generation sequencing panel: a retrospective study on a consecutive cohort.Semantic proximity Read ↗

Molecular subtypes of endometrial cancer: Implications for adjuvant treatment strategies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.